Item Type | Name |
Concept
|
Hydroxyurea
|
Academic Article
|
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
|
Academic Article
|
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
|
Academic Article
|
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
|
Academic Article
|
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
|
Academic Article
|
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
|
Academic Article
|
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
|
Academic Article
|
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
|
Academic Article
|
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.
|
Academic Article
|
Oral 5-FU alternatives for the treatment of head and neck cancer.
|
Academic Article
|
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
|
Academic Article
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
Academic Article
|
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
|
Academic Article
|
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
|
Academic Article
|
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
|
Academic Article
|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
|
Academic Article
|
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
|
Academic Article
|
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer.
|
Academic Article
|
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
|
Academic Article
|
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
|
Academic Article
|
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
|
Academic Article
|
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.
|
Academic Article
|
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
|
Academic Article
|
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
|
Academic Article
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
Academic Article
|
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
|
Academic Article
|
Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer.
|
Academic Article
|
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
|
Academic Article
|
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
|
Academic Article
|
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
|
Academic Article
|
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
|
Academic Article
|
Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.
|
Academic Article
|
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
|
Academic Article
|
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.
|
Academic Article
|
Concomitant chemoradiotherapy for non-small cell lung cancer.
|
Academic Article
|
The role of paclitaxel in the treatment of head and neck cancer.
|
Academic Article
|
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
|
Academic Article
|
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
|
Academic Article
|
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer.
|
Academic Article
|
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
|
Academic Article
|
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
|
Academic Article
|
Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.
|
Academic Article
|
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.
|
Academic Article
|
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
|
Academic Article
|
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFeradeā¢ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
|
Academic Article
|
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
|
Academic Article
|
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma.
|